Assessing The Cost-Effectiveness of Secukinumab Compared To Tnf Inhibitors As Second Line Biologic Treatment In Psoriatic Arthritis
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1113
https://www.valueinhealthjournal.com/article/S1098-3015(16)32479-2/fulltext
Title :
Assessing The Cost-Effectiveness of Secukinumab Compared To Tnf Inhibitors As Second Line Biologic Treatment In Psoriatic Arthritis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32479-2&doi=10.1016/j.jval.2016.09.1113
First page :
A538
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1042